<li>adalimumab<p>adalimumab and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>adenovirus types 4 and 7 live, oral<p>sirolimus decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.</p></li><li>alefacept<p>alefacept and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>anakinra<p>anakinra and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>anthrax vaccine<p>sirolimus decreases effects of anthrax vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>antithymocyte globulin equine<p>antithymocyte globulin equine and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>antithymocyte globulin rabbit<p>antithymocyte globulin rabbit and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>azathioprine<p>azathioprine and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>basiliximab<p>basiliximab and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>bcg vaccine live<p>sirolimus decreases effects of bcg vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>blinatumomab<p>blinatumomab increases levels of sirolimus by decreasing metabolism. Avoid or Use Alternate Drug. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index.</p></li><li>bosentan<p>bosentan will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>budesonide<p>budesonide will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>butalbital<p>butalbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>canakinumab<p>canakinumab and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ceritinib<p>ceritinib increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concurrent use of CYP3A substrates known to have narrow therapeutic indices or substrates primarily metabolized by CYP3A during treatment with ceritinib; if use of these medications is unavoidable, consider dose.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clobetasone<p>clobetasone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cobicistat<p>cobicistat will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>conivaptan<p>conivaptan will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>cortisone<p>cortisone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>darunavir<p>darunavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>dasatinib<p>dasatinib will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>delavirdine<p>delavirdine will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>diphtheria &amp; tetanus toxoids<p>sirolimus decreases effects of diphtheria &amp; tetanus toxoids by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>diphtheria &amp; tetanus toxoids/ acellular pertussis vaccine<p>sirolimus decreases effects of diphtheria &amp; tetanus toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>diphtheria &amp; tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine<p>sirolimus decreases effects of diphtheria &amp; tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>etanercept<p>etanercept and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>etravirine<p>etravirine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>everolimus<p>everolimus and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>fludrocortisone<p>fludrocortisone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>glatiramer<p>glatiramer and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>golimumab<p>golimumab and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>haemophilus influenzae type b vaccine<p>sirolimus decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis a vaccine inactivated<p>sirolimus decreases effects of hepatitis a vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis a/b vaccine<p>sirolimus decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis a/typhoid vaccine<p>sirolimus decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>hepatitis b vaccine<p>sirolimus decreases effects of hepatitis b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>human papillomavirus vaccine, bivalent<p>sirolimus decreases effects of human papillomavirus vaccine, bivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p></li><li>human papillomavirus vaccine, nonavalent<p>sirolimus decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p></li><li>human papillomavirus vaccine, quadrivalent<p>sirolimus decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p></li><li>hydrocortisone<p>hydrocortisone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>hydroxychloroquine sulfate<p>hydroxychloroquine sulfate and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>idelalisib<p>idelalisib will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>indinavir<p>indinavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>infliximab<p>infliximab and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>influenza virus vaccine quadrivalent<p>sirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>influenza virus vaccine quadrivalent, intranasal<p>sirolimus decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>influenza virus vaccine trivalent<p>sirolimus decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>influenza virus vaccine trivalent, adjuvanted<p>sirolimus decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ivacaftor<p>ivacaftor increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.<span><br><br></span>ivacaftor, sirolimus.
Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.</p></li><li>japanese encephalitis virus vaccine<p>sirolimus decreases effects of japanese encephalitis virus vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>leflunomide<p>leflunomide and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Lumacaftor is a strong inducer of CYP3A. Avoid coadministration with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index.</p></li><li>lumefantrine<p>lumefantrine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>marijuana<p>marijuana will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>measles (rubeola) vaccine<p>sirolimus decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>measles mumps and rubella vaccine, live<p>sirolimus decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>measles, mumps, rubella and varicella vaccine, live<p>sirolimus decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>meningococcal a c y and w-135 polysaccharide vaccine combined<p>sirolimus decreases effects of meningococcal a c y and w-135 polysaccharide vaccine combined by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>methylprednisolone<p>methylprednisolone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>modafinil<p>modafinil will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>muromonab cd3<p>muromonab cd3 and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>mycophenolate<p>mycophenolate and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>nafcillin<p>nafcillin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>pneumococcal vaccine 13-valent<p>sirolimus decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>pneumococcal vaccine heptavalent<p>sirolimus decreases effects of pneumococcal vaccine heptavalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>pneumococcal vaccine polyvalent<p>sirolimus decreases effects of pneumococcal vaccine polyvalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>poliovirus vaccine inactivated<p>sirolimus decreases effects of poliovirus vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>poliovirus vaccine live oral trivalent<p>sirolimus decreases effects of poliovirus vaccine live oral trivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>prednisolone<p>prednisolone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>prednisone<p>prednisone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>pregabalin<p>sirolimus, pregabalin.
Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.</p></li><li>primidone<p>primidone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>quinidine<p>quinidine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rabies vaccine<p>sirolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.</p></li><li>rabies vaccine chick embryo cell derived<p>sirolimus decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifampin<p>rifampin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>rilonacept<p>rilonacept and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>rotavirus oral vaccine, live<p>sirolimus decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>rubella vaccine<p>sirolimus decreases effects of rubella vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>smallpox (vaccinia) vaccine, live<p>sirolimus decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>tacrolimus<p>sirolimus and tacrolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>temsirolimus<p>sirolimus and temsirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>tetanus toxoid adsorbed or fluid<p>sirolimus decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>tick borne encephalitis vaccine<p>sirolimus decreases effects of tick borne encephalitis vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>tocilizumab<p>tocilizumab and sirolimus both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>tofacitinib<p>sirolimus, tofacitinib.
Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>tongkat ali<p>sirolimus and tongkat ali both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>topiramate<p>topiramate will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>travelers diarrhea and cholera vaccine inactivated<p>sirolimus decreases effects of travelers diarrhea and cholera vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>triamcinolone<p>triamcinolone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>typhoid polysaccharide vaccine<p>sirolimus decreases effects of typhoid polysaccharide vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>typhoid vaccine live<p>sirolimus decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>ustekinumab<p>sirolimus and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.</p></li><li>varicella virus vaccine live<p>sirolimus decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>venetoclax<p>venetoclax will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. In vitro data suggest venetoclax may inhibit P-gp substrates at therapeutic dose levels in the gut. Avoid coadministration of narrow therapeutic index P-gp substrates with venetoclax. If a narrow therapeutic index P-gp substrate must be used, it should be taken at least 6 hr before venetoclax.</p></li><li>verapamil<p>verapamil will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>yellow fever vaccine<p>sirolimus decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>zoster vaccine live<p>sirolimus decreases effects of zoster vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.</p></li>